摘要
目的观察奥拉西坦治疗脑卒中后认知功能障碍疗效与不良反应。方法从本院2012年9月~2016年9月收治的100例脑卒中后认知功能障碍患者作为研究对象,随机分为对照组(50例)及观察组(50例)。选用吡拉西坦药物治疗为对照组,选用奥拉西坦药物治疗为观察组。治疗前后,采用简易智能(MMSE)、日常生活能力(ADL)、蒙特利尔(Mo CA)认知评估量表评估两组患者,通过计算评分变化率,分析治疗有效率,并对不良反应进行观察、统计。结果经不同方法治疗,观察组MMSE改善情况优于对照组,差异具有统计学意义(P<0.05);观察组ADL改善情况优于对照组,两组差异显著,具有统计学意义(P<0.05);观察组Mo CA改善情况优于对照组,差异具有统计学意义(P<0.05);对照组及观察组不良反应发生率分别为12.0%、6.0%,两组存在差异,但无统计学意义(P>0.05)。结论与吡拉西坦药物相比,奥拉西坦药物可显著改善患者认知功能、获得满意疗效、减少不良反应,建议在临床中大力推广应用。
Objective To observe the efficacy and adverse effects of Oxiraeetam for treatment of cognitive dysfunction in stroke patients. Methods 100 patients with cognitive impairment after stroke in our hospital were randomly divided into control group （ n =50 ） and observation group （ n =50 ） . Control group were treated with piracetam, and the observation group were treated with oxiraeetam. Before and after the treatment, the Mini - Mental State Examination （ MMSE ）, ability of daily life （ ADL ） and Montreal cognitive assessment scale （ MoCA ） were used to evaluated the symptoms in two groups. The percentage change from baseline were used to evaluate the treatment efficiency, and the adverse reactions were also analyzed. Results After treatment, the improvement of MMSE the observation group is better than that of the control group （ P〈 0.05 ）; the improvement of ADL of observation group is much better than the control group （P 〈 0.05 ）; the improvement of MoCA in the observation group were better than those in the control group （ P 〈 0.05 ） ; the incidence of adverse reaction of the control group and the observation group were 12 % and 6 % respectively, but the group difference is not significant （P 〉 0.05 ） . Conclusion Compared with piracetam, oxiraeetam can significantly improve patients＇ cognitive function, obtain satisfactory curative effect, reduce adverse reactions. Thus, oxiracetam is recommended to promote the cognitive function in stroke patients.
出处
《国际精神病学杂志》
2017年第3期487-489,共3页
Journal Of International Psychiatry
关键词
脑卒中
认知功能障碍
奥拉西坦
疗效
不良反应
Stroke
Cognitive dysfunction
Oxiracetam
Curative effect
Adverse reaction
